INDSWFTLAB.BO

Established in 1995 and headquartered in Manimajra, India, Ind-Swift Laboratories Limited is an Indian pharmaceutical company primarily focused on the creation, production, and commercialization of active pharmaceutical ingredients (APIs) and sophisticated intermediate compounds. Their extensive portfolio of APIs spans a wide array of therapeutic categories, encompassing macrolide antibiotics, cardiovascular treatments, antihistamines, antidiabetic medications, antipsychotic drugs, bone resorption inhibitors, antimigraine remedies, therapies for Parkinson's disease and hyperparathyroidism, analgesics, aromatase inhibitors, nootropics, antidiarrhoeal/antiprotozoal agents, anticholinergics, sedatives, hypnotics, antineoplastics, and products addressing ADHD symptoms. Beyond APIs, the company offers essential reference standards and impurities for a diverse range of pharmaceutical substances, including specific compounds like acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. Additionally, Ind-Swift provides comprehensive contract research and manufacturing services (CRAMS) and distributes its products internationally.